Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related deaths among women in the United States ([@bib11]; [@bib46]). Although there has been interest in the potential influence of dietary factors and dietary patterns on breast cancer incidence ([@bib51]; [@bib13]; [@bib39]) and survival ([@bib7]; [@bib27]; [@bib17]), the findings have been mixed. In addition, observational ([@bib20], [@bib19]; [@bib24]) and animal intervention studies ([@bib25]; [@bib4]) have found associations of inflammation with breast cancer risk, and dietary patterns have been shown to be linked to inflammation ([@bib12]; [@bib29]; [@bib2]).

The recent development of a dietary inflammatory index (DII) ([@bib44]) provides a new tool to evaluate diets on a continuum from maximally anti-inflammatory to maximally pro-inflammatory. The DII was construct validated in a variety of studies, including the Women\'s Health Initiative (WHI), and found to predict concentrations of several inflammatory markers ([@bib45], [@bib41]; [@bib50]). Pro-inflammatory DII scores have also been consistently associated with higher risk of colorectal cancer in previous studies ([@bib42]; [@bib57]; [@bib48]; [@bib54]; [@bib49]). However, two previous studies found conflicting results for the association of the DII with breast cancer incidence ([@bib16]; [@bib43]). In the current study we utilised the DII to investigate the association of the inflammatory potential of diet with postmenopausal breast cancer incidence and death using data from the WHI.

Materials and methods
=====================

Participants
------------

The WHI was designed to address the major causes of morbidity and mortality among postmenopausal women. The design of the WHI has been previously described ([@bib56]). Briefly, WHI investigators enrolled 161 808 postmenopausal women 50 to 79 years old with a predicted \>3-year survival in 40 sites in the United States between 1993 and 1998. Subjects were enrolled into one or more of three Clinical Trial (CT) groups (*n*=68 132) or the Observational Study (*n*=93 676). The CT had additional eligibility criteria and women were excluded from the Dietary Modification (DM) Trial if their diets were reported to have \<32% energy from fat as assessed by a food frequency questionnaire (FFQ) ([@bib37]). The WHI protocol was approved by the institutional review boards at the Clinical Coordinating Center (CCC) at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) and at each of the 40 Clinical Centers ([@bib56]).

Diet assessment
---------------

During screening for the WHI, all participants completed a standardised self-administered 122-item FFQ developed for the WHI to estimate average daily nutrient intake over the previous 3-month period. These data served as the baseline dietary measures. The FFQ data were considered complete if all adjustment questions, all summary questions, 90% of the foods, and at least one-half of every food group section was completed ([@bib36]; [@bib56]). The nutrient database, linked to the University of Minnesota Nutrition Data System for Research (NDSR) ([@bib33]), is based on the US Department of Agriculture Standard Reference Releases and manufacturer information. The WHI FFQ has produced results comparable to those from four 24-h dietary recall interviews and 4 days of food diaries recorded within the WHI study population ([@bib37]).

Description of the DII
----------------------

Details of the development ([@bib44]) and construct validation ([@bib45]; [@bib50]) of the DII have been described elsewhere. Briefly, an extensive literature search was performed to identify articles published in peer-reviewed journals reporting on studies that examined the association between dietary factors and six inflammatory markers (interleukin (IL)-1*β*, IL-4, IL-6, IL-10, tumour necrosis factor-*α* (TNF*α*), and C-reactive protein (CRP)). A total of 1943 eligible articles published through 2010 were indexed and scored to derive component-specific inflammatory effect scores. In the process of reading and scoring these articles, a total of 45 specific foods and nutrients (components of the DII) were identified.

Actual dietary intake data derived from baseline WHI FFQ were standardised to a representative global diet database constructed based on 11 data sets from diverse populations in different parts of the world. The standardised dietary intake data were then multiplied by the literature-derived inflammatory effect scores for each DII component, and summed across all components, to obtain the overall DII ([@bib44]). A higher DII score indicates a more inflammatory diet and a lower (i.e., more negative) DII score indicates a less inflammatory diet. In the WHI FFQ, 32 of the 45 original DII components were available for inclusion in the overall DII (see [@bib50] and [Table 1](#tbl1){ref-type="table"} for the list of the 32 DII components included in the WHI DII calculation). The components ginger, turmeric, garlic, oregano, pepper, rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, and anthocyanidins that are included in the original DII calculation ([@bib44]) were not included in the current study because they were not available from the WHI FFQ. The DII has been construct validated in the WHI and found to significantly predict concentrations of IL-6 and TNF*α* receptor 2 expression ([@bib50]).

Outcome ascertainment
---------------------

Outcomes included breast cancer event (diagnosis of invasive breast cancer or confirmation of breast cancer-related death) and time to breast cancer event. As previously described ([@bib9]), breast cancers were initially verified by medical record and pathology report review by physician adjudicators at each clinical centre, with final adjudication centrally by WHI cancer coders ([@bib9]).

Breast cancer subtypes for analysis were defined based on oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status ([@bib5]), and combined as triple-negative (ER−, PR−, HER2−); luminal A (ER+ and/or PR+, HER2−); luminal B (ER+ and/or PR+, HER2+); and ER−, PR−, HER2+ subtypes ([@bib35]). The histological subtypes were defined based on Surveillance Epidemiology and End Results program morphology codes. These included invasive ductal carcinoma (8500/3) and invasive lobular carcinoma (8520/2). The *in situ* breast cancer cases were not included.

Time-to-breast-cancer-event (diagnosis or death) was defined as days from enrolment or randomisation until invasive breast cancer diagnosis or confirmation of breast cancer death. Censoring time for breast cancer incidence models was defined as days from enrolment or randomisation until death or last contact occurring on or before 29 August 2014 in participants without breast cancer; for breast cancer death (fatal breast cancer) models, censoring time was the number of days from enrolment/randomisation until last contact occurring on or before 29 August 2014 in participants who were still alive.

Statistical analyses
--------------------

Data on 149 790 women from both the OS and the CT were considered for the current analyses. Through 29 August 2014, 7495 women were diagnosed with invasive breast cancer and 667 breast cancer deaths were confirmed. The following exclusion criteria were applied to both sets of analyses: any cancer (except non-melanoma skin cancer) before study entry or missing prior cancer status (*n*=10 858), mastectomy at baseline (*n*=268), any cancer (except non-melanoma skin cancer) diagnosed within 2 years from baseline during follow-up (*n*=2032), implausible reported total energy intake values (⩽600 or ⩾5000 kcal per day; *n*=4219) or extreme body mass index (BMI) values (\<15 or\>50 kg m^−2^; *n*=733). Participants with missing data in the covariates listed below (*n*=8892) were excluded, leaving a total of 122 788 participants for the current analyses. Frequencies and percentages were used to describe the distribution of covariates across quintiles of the DII.

We used Cox regression models to calculate hazard ratios (HRs), associated 95% confidence intervals (95% CIs), and linear trends for invasive breast cancer, breast cancer subtypes, breast cancer stages, and breast cancer-related death, for DII quintiles with adjustment for multiple covariates. The lowest DII quintile (representing the most anti-inflammatory diet) was the referent for all models. The analysis of breast cancer death was a full cohort analysis of fatal breast cancer outcomes. Potential effect modification of the association between the DII and breast cancer incidence and death by age, BMI, regular nonsteroidal anti-inflammatory drug (NSAID) use, and hormone use was investigated by including DII × covariate interaction terms in the Cox regression models; none of the interaction terms was significant at *P*\<0.10. Tests of linear trend across DII quintiles were computed by assigning the median value of each quintile to each participant in the quintile and this ordinal variable was entered into models and its *P*-value evaluated for significant trend.

Data on potential confounders were collected by standardised self-administered questionnaires on demographics, medical history, and lifestyle factors. In bivariate analyses including the DII and each of these potential confounders, a change of ⩾10% in the HR comparing the univariate model with DII only with the bivariate model resulted in inclusion of the covariate in the fully adjusted model. Multivariable Cox regression models were adjusted for the following covariates: age (continuous, years), race/ethnicity (European American, African American, Hispanic, Asian or Pacific Islander, and Other), BMI (underweight (15 to \<18.5 kg m^−2^), normal weight (18.5 to \<25 kg m^−2^), overweight (25 to \<30 kg m^−2^), and obese (30 to 50 kg m^−2^)); physical activity (PA) categorised based on current public health recommendations ([@bib10]), as meeting or not meeting PA recommendations (⩾150 min per week of moderate intensity PA or ⩾60 min per week of vigorous intensity PA *vs* \<150 min per week of moderate intensity PA or \<60 min per week of vigorous intensity PA, respectively), education (some high school or lower educational level, high school graduate/some college or associate degree, ⩾4 years of college), family income (\<\$10 000, \$10 000--\$19 999, \$20 000--\$34 999, \$35 000--\$49 999, \$50 000--\$74 999, \$75 000--\$99 999, \$100 000--\$149 999, ⩾\$150 000), smoking status (current, past, and never), family history of breast cancer (yes/no), mammography use within 2 years of baseline (yes/no), age at menarche (\<10, 11--15, ⩾16 years), number of live births (none, 1--3, ⩾4), oophorectomy status (no ovaries removed, one or both ovaries removed), hormone therapy use (never, former, current), regular (at least twice a week for the previous 2 weeks; [@bib8]) use of NSAID (yes/no), DM arm (intervention, control, not randomised to DM), HRT arm (oestrogen-alone intervention, oestrogen-alone control, oestrogen and progesterone intervention, oestrogen and progesterone control, not randomised to HRT), calcium and vitamin D (CaD) trial arm (intervention, control, not randomised to CaD), and total energy intake (Kcal per day). The proportional hazards assumption was assessed for each covariate using Martingale-based residuals. The CaD arm violated the assumption in both the incidence and death analyses, and all Cox regression models were thus stratified by CaD.

We conducted several sensitivity analyses; first, we excluded women diagnosed with (*n*=1517), or who died from (*n*=11), breast cancer within 3 years from baseline to reduce the likelihood that results reflected the presence of subclinical disease at baseline ([@bib32]; [@bib38]). Second, we conducted incidence and death analyses excluding women diagnosed with any cancer at any time point before the diagnosis of breast cancer. Third, we stratified by WHI study arm (OS and CT) to ensure that results were not sensitive to the WHI study design. Finally, we compared women with and without missing data in the covariates included in the multivariable models to ensure that the women excluded because of missing data were not systematically different from the women retained for final analysis.

Results
=======

After applying all exclusion criteria, a total of 7495 cases of incident invasive breast cancer (average 15.1 years (1 848 542.1 person-years) of follow-up) and 667 breast cancer deaths (average 16.6 years (1 672 710.1 person-years) of follow-up) were available for analyses. The mean (±s.d.) DII score was −0.78 (±2.61), and ranged from a maximally anti-inflammatory score of −7.06 to a maximally pro-inflammatory score of +5.79. [Table 1](#tbl1){ref-type="table"} presents the distribution of participants\' characteristics across quintiles of the DII. Participants consuming the most inflammatory diets (classified in the highest quintile) were more likely to be obese, African American or Hispanic, not meeting public health recommendations for physical activity, and reported a low level of education, compared with their counterparts who consumed more anti-inflammatory diets (i.e., likely to fall into lower DII quintiles, [Table 1](#tbl1){ref-type="table"}).

There was no statistically significant association between the DII and risk of overall breast cancer incidence. In the multivariable-adjusted model, the HR (and 95% CI) comparing women in the highest with those in the lowest DII quintile was 0.99 (95% CI, 0.91--1.07; [Table 2](#tbl2){ref-type="table"}). There was a positive association between the DII and overall breast cancer death in the fourth and fifth quintiles compared with the lowest quintile of DII in the age and energy intake-adjusted model (HR~Q4*vs*Q1~, 1.51; 95% CI, 1.18--1.94 and HR~Q5*vs*Q1~, 1.53; 95% CI, 1.18--2.00; *P*~trend~, 0.0005). The association between the DII and breast cancer death was slightly attenuated, but persisted even after controlling for BMI, physical activity, education, smoking status, hormone therapy use, regular NSAID use, DM arm, and screening history (HR~Q4*vs*Q1~, 1.38; 95% CI, 1.07--1.79 and HR~Q5*vs*Q1~, 1.33; 95% CI, 1.01--1.76; *P*~trend~=0.03; [Table 2](#tbl2){ref-type="table"}). Both BMI and physical activity were largely responsible for the attenuation of HRs in the multivariable-adjusted model. The HRs in the fourth and fifth DII quintiles without adjusting for BMI and physical activity were: HR~Q4*vs*Q1~, 1.48; 95% CI, 1.15--1.90 and HR~Q5*vs*Q1~, 1.46; 95% CI, 1.11--1.93; *P*~trend~=0.002.

[Table 3](#tbl3){ref-type="table"} presents HRs for the association between DII quintiles and subtypes and stage of breast cancer. There was a tendency towards higher risk of breast cancer subtypes that included HER2+ (i.e., luminal B (ER+ and/or PR+, HER2+) and (ER−, PR−, HER2+) subtypes) with higher DII scores that did not attain statistical significance. Irrespective of ER or PR status, risk of HER2+ breast cancer subtype was significantly higher in women in quintile 4 compared with those in quintile 1 (HR, 1.33; 95% CI, 1.05--1.67); however, risk appeared to be attenuated (and nonsignificant) in quintile 5 (HR, 1.11; 95% CI, 0.85--1.44; *P*~trend~=0.24). There was no association between the DII and localised breast cancer. However, there was a suggestion of an inverse association between the DII and regional/distant disease (HR~Q5*vs*Q1~, 0.84; 95% CI, 0.79--1.00; *P*~trend~=0.03).

In sensitivity analyses ([Table 4](#tbl4){ref-type="table"}), results for overall breast cancer incidence and breast cancer death did not materially change when we excluded breast cancer cases and deaths that occurred within 3 years from baseline. The findings also did not change materially when all other cancers diagnosed before breast cancer were excluded ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Results in the OS were not materially different than in the CT when stratified by WHI study participation (data not shown). Comparing demographic and other characteristics of women who were excluded because of missing data *vs* those included in the analyses did not reveal substantial differences between these two populations (data not shown).

Discussion
==========

In this large prospective investigation of pre-diagnosis dietary inflammatory potential in postmenopausal women, a more pro-inflammatory diet was not associated with higher risk of overall breast cancer incidence. However, there was a significantly higher risk of breast cancer death with higher baseline DII scores in a full cohort analysis. In subgroup analyses, higher DII was also associated with a higher risk of HER2+ breast cancer in the fourth quintile of DII score, but not in the fifth (highest) quintile.

Similar to our finding, most prospective observational studies ([@bib47]; [@bib51]; [@bib1]; [@bib13]) and clinical trials ([@bib39]) have not found a significant association between higher diet quality as assessed by other dietary patterns and overall breast cancer risk. Diet quality is inversely related to the inflammatory potential of diet, that is, higher quality diets would have lower DII scores ([@bib55]). In the WHI-DM Trial, where a low-fat dietary pattern was assessed, after 9.1 years of follow up, there appeared to be fewer invasive breast cancers in the dietary intervention group. However, the difference was not statistically significant (HR, 0.91; 95% CI, 0.83--1.01) ([@bib39]). A prospective study examining the association of several diet quality scores, including the Healthy Eating Index, Alternate Healthy Eating Index, Diet Quality Index-Revised, and Recommended Food Score (the sum of 23 recommended food items consumed at least weekly), did not find a significant association with overall breast cancer risk, though risk of ER-negative tumours was lower with higher Recommended Food Scores ([@bib14]).

Two studies have found conflicting results of the association between the DII and breast cancer incidence. A case--control study from Germany found no association ([@bib16]), whereas a prospective cohort study in Sweden reported a positive association ([@bib43]) between higher DII scores and risk of breast cancer. Our study of postmenopausal American women may differ from these two previous studies because of differences in dietary inflammatory potential of the study populations. The mean (±s.d.) DII scores in the Swedish (2.67±1.47) and German (0.85±1.30) studies were more pro-inflammatory compared with the current study (−0.78±2.61).

It is possible that diet may differentially influence breast cancer development based on the cancer phenotype. Similar to our differential findings by HER2 subtypes, another prospective study, in Italy, found an association between higher consumption of salad vegetables and lower risk of HER2+ breast cancer, and a suggestion of higher risk of HER2− breast cancer with more prudent dietary patterns ([@bib40]). The WHI low-fat intervention trial investigated breast cancer risk by tumour characteristics including hormone receptor status. The HR estimate was not related to ER status, but was lower for PR-negative tumours than for PR-positive tumours (*P*=0.04). When tumours were classified by both ER and PR status, there was an indication (*P*=0.04) of HR variation with stronger evidence for a reduction in the occurrence of tumours that were ER positive and PR negative. The HER2 status was not available for breast cancers diagnosed early in that trial and was therefore not investigated ([@bib39]). Overall, findings from this previous study of the WHI-DM provide further support for a potential differential role of diet on breast cancer risk by cancer phenotype. Given the lack of dose response, and smaller number of HER2+ cases in the current study, future studies examining association between diet quality and breast cancer phenotypes are warranted. Similarly, the suggestion of an inverse trend between the DII and risk of regional/distant breast cancer was unexpected as there is no precedent for a similar result in the literature.

Our result of higher risk of breast cancer death with higher consumption of pro-inflammatory diets is similar to the finding by [@bib30]), who observed a moderate association between pre-diagnosis diet and risk of breast cancer death. They found a 25% lower risk of breast cancer-related death (HR, 0.75; 95% CI, 0.56--1.00; *P*~trend~=0.06) for women in the highest quartile compared with the lowest quartile of Recommended Food Score after adjusting for potential confounding factors ([@bib30]). The potential role of chronic inflammation in breast cancer death is supported by evidence from studies on the association between inflammatory markers and breast cancer mortality. Higher concentrations of most inflammatory markers including CRP, IL-6, and TNF*α* have been associated with higher risk of breast cancer mortality ([@bib3]; [@bib23]; [@bib18]).

The attenuated association between higher DII scores and breast cancer death when we additionally adjusted for BMI and physical activity may partially be because of confounding by these two energy-balance covariates. Obesity or weight gain has been associated with the quality of dietary intake ([@bib15]) and with breast cancer prognosis ([@bib6]; [@bib53]). However, it is also possible that obesity, a state of low-grade chronic inflammation ([@bib52]; [@bib28]), may partly mediate this association. Evidence for mediation is strengthened by findings from well-designed meta-analyses that combine data from prospective studies of dietary determinants of long-term weight gain, and randomised clinical trials evaluating short-term effects of specific dietary factors on weight changes ([@bib31]; [@bib26]; [@bib34]). Therefore, the risk of breast cancer death from consuming highly pro-inflammatory diets is likely higher than the 33% (comparing extreme DII quintiles) we obtained after additional adjustment for BMI and physical activity. Future studies are needed to examine the inflammatory potential of post-diagnosis diet given the suggestion from the current study that dietary inflammatory potential before diagnosis is related to breast cancer death.

The study strengths include the use of the DII specifically designed to assess the inflammatory potential of diet; a large, well-characterised study population; a long follow-up period; and central adjudication of breast cancer outcomes. We conducted several sensitivity analyses, including the investigation of the possibility that early malignant lesions might have affected the dietary intake or the report thereof by excluding participants who were diagnosed with invasive breast cancer or who died from it within 3 years from baseline ([@bib32]; [@bib38]), and our findings were unchanged ([Table 4](#tbl4){ref-type="table"}).

Study limitations include known measurement error in using an FFQ for diet assessment ([@bib21]; [@bib22]) and the use of a single FFQ at one time point (baseline) only, though diet could change during follow-up. We adjusted for study arm in the multivariable models and investigated the longitudinal stability of DII scores in the WHI-OS and DM control arm participants in a separate study and found DII scores not to change significantly over time ([@bib49], [@bib50], and unpublished results). In addition, 13 dietary components of the DII were missing from the WHI FFQ, and all 13 of these missing items are anti-inflammatory. Thus, the DII may have a lower predictive ability in this predominantly White and highly educated study population with a more healthful diet consuming food items not on the WHI FFQ list. It is important to note, though, that in the construct validation of the DII in the WHI, the DII computed based on the 32 components available in the WHI FFQ predicted concentrations of inflammatory markers ([@bib50]). The DII score calculated from the 32 available components ranged from −7.1 to +5.8, which is higher than the range of −5.4 to +5.8 obtained in the first DII construct validation study using data from fifteen 24-h dietary recalls with 44 of the 45 DII components ([@bib45]), indicating that the range of DII may be more dependent on the amount of foods actually consumed rather than on the number of available components. Missing data in all covariates included in the multivariable models could potentially bias our HR estimates; however, the women excluded because of missing data were similar to those retained on all characteristics included in [Table 1](#tbl1){ref-type="table"}. In addition, when we excluded major contributors of missing data such as family history of breast cancer and NSAID use, there were no material differences in HR estimates (data not shown). Although we adjusted for a large number of potential confounders, there may still exist potential residual or unmeasured confounding. In addition, given the number of tests in [Table 3](#tbl3){ref-type="table"}, we cannot rule out that our findings for HER2+ subtype or regional/distant disease are because of chance, though all tests were pre-determined.

Data on treatment were not available, although we did not expect treatment to have an impact on these analyses related to baseline diet estimated well before a breast cancer diagnosis. In the death analyses, we adjusted for race/ethnicity, physical activity, and education, among other potential confounders, but did not adjust for stage (and other tumour characteristics) because stage is more likely a mediator or modifier than a confounder of the association between baseline pre-diagnosis diet and breast cancer death. However, stage may confound the association between post-diagnosis diet and survival from breast cancer, as patients may be advised or choose to eat differently based on tumour characteristics or treatment options (that are often based on tumour characteristics). Post-diagnosis diet was not available for all WHI subjects diagnosed with cancer and, therefore, was not examined in the current analyses.

Conclusion
==========

In this large prospective study of postmenopausal women, a diet characterised by high inflammatory potential, as indicated by higher DII scores, was associated with higher risk of breast cancer death but not incidence of overall breast cancer. Our findings suggest that lowering the inflammatory potential of a woman\'s diet may be a potential means for reducing the risk of breast cancer death. Future studies should explore whether dietary intervention focused on inflammation could affect the risk of dying from breast cancer.
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###### Participant baseline characteristics (*n*, %) by quintiles (Q) of the dietary inflammatory index (DII)[a](#t1-fn2){ref-type="fn"}; Women\'s Health Initiative (*n*=122 788); 1993--1998

  **Characteristic**                                       **Q1 (−7.055, \<−3.142) (more anti-inflammatory diet)**   **Q2 (−3.142, \<−2.016)**   **Q3 (−2.016, \<−0.360)**   **Q4 (−0.360, \<1.898)**   **Q5 (1.898, \<5.519) (more pro-inflammatory diet)**
  ------------------------------------------------------- --------------------------------------------------------- --------------------------- --------------------------- -------------------------- ------------------------------------------------------
  Age, year (mean±s.d.)                                                           63.5±7.1                                   63.5±7.1                    63.2±7.2                    62.8±7.1                                 62.3±7.2
  **Body mass index, (kg m^−2^)**                                                                                                                                                                      
  Underweight (15 to \<18.5)                                                      266 (1.1)                                  189 (0.8)                   170 (0.7)                  196 (0.8)                                159 (0.7)
  Normal weight (18.5 to \<25)                                                  10 018 (40.8)                               8874 (36.1)                 8297 (33.8)                7595 (30.9)                              7077 (28.8)
  Overweight (25 to \<30)                                                        8357 (34.0)                                8605 (35.0)                 8667 (35.3)                8685 (35.4)                              8652 (35.2)
  Obese (30 to 50)                                                               5916 (24.1)                                6891 (28.1)                 7424 (30.2)                8081 (32.9)                              8669 (35.3)
  **Race/ethnicity**                                                                                                                                                                                   
  Asian or Pacific Islander                                                      1077 (4.4)                                  504 (2.1)                   520 (2.1)                  609 (2.5)                                413 (1.7)
  African-American                                                               1065 (4.3)                                 1347 (5.5)                  1743 (7.1)                  2187 (8.9)                              3523 (14.3)
  Hispanic/Latino                                                                 495 (2.0)                                  589 (2.4)                   847 (3.5)                  940 (3.8)                                1368 (5.6)
  European American                                                             21 559 (87.8)                              21 793 (88.7)               21 081 (85.8)              20 484 (83.4)                            18 843 (76.7)
  Other                                                                           361 (1.5)                                  326 (1.3)                   367 (1.5)                  337 (1.4)                                410 (1.7)
  **Physical activity (PA)**                                                                                                                                                                           
  Not meeting PA recommendations                                                 7890 (32.1)                               10 489 (42.7)               11 643 (47.4)              12 261 (49.9)                            14 483 (59.0)
  Meeting PA recommendations                                                    16 667 (67.9)                              14 070 (57.3)               12 915 (52.6)              12 296 (50.1)                            10 074 (41.0)
  **Educational level**                                                                                                                                                                                
  Some high school or lower educational level                                     562 (2.3)                                  874 (3.6)                  1064 (4.3)                  1264 (5.1)                               1874 (7.6)
  High school graduate/some college or associate degree                         11 337 (46.2)                              13 304 (54.1)               13 819 (56.3)              13 962 (56.9)                            15 308 (62.4)
  ⩾4 Years of college                                                           12 658 (51.5)                              10 381 (42.3)                9675 (39.4)                9331 (38.0)                              7375 (30.0)
  **Smoking status**                                                                                                                                                                                   
  Never                                                                         12 203 (49.7)                              12 501 (50.9)               12 616 (51.4)              12 457 (50.7)                            12 440 (50.7)
  Past                                                                          11 465 (46.7)                              10 735 (43.7)               10 287 (41.9)              10 341 (42.1)                             9553 (38.9)
  Current                                                                         889 (3.6)                                 1323 (5.4)                  1655 (6.7)                  1759 (7.2)                              2564 (10.4)
  **Family history of breast cancer**                                                                                                                                                                  
  No                                                                            19 633 (80.0)                              19 699 (80.2)               19 694 (80.2)              19 798 (80.6)                            20 025 (81.5)
  Yes                                                                            4924 (20.0)                                4860 (19.8)                 4864 (19.8)                4759 (19.4)                              4532 (18.5)
  **NSAID use**                                                                                                                                                                                        
  No                                                                             9749 (39.7)                                9199 (37.5)                 9629 (39.2)               10 109 (41.2)                            10 509 (42.8)
  Yes                                                                           14 808 (60.3)                              15 360 (62.5)               14 929 (60.8)              14 448 (58.8)                            14 048 (57.2)

Abbreviation: NSAID=nonsteroidal anti-inflammatory drug.

The DII components available in the Women\'s Health Initiative (WHI) food frequency questionnaire (FFQ) were: alcohol, *β*-carotene, caffeine, carbohydrates, cholesterol, total energy, total fat, saturated fat, fiber, folic acid, iron, magnesium, niacin, riboflavin, thiamine, zinc, monounsaturated fatty acid (fa), polyunsaturated fa, omega 3 fa, omega 6 fa, trans fat, protein, selenium, vitamins B12, B6, A, C, D, E, onion, green/black tea, and isoflavones; the following components not available in the WHI FFQ were: ginger, turmeric, garlic, oregano, rosemary, pepper, eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, and anthocyanidins.

###### Hazard ratios of the association between the dietary inflammatory index (DII) and breast cancer incidence and death; Women\'s Health Initiative (*n*=122 788), 1993--2014

  **Breast cancer incidence**                                                  **Q1 (−7.055, \<−3.142) (more anti-inflammatory diet)**   **Q2 (−3.142, \<−2.016)**   **Q3 (−2.016, \<−0.360)**   **Q4 (−0.360, \<1.898)**   **Q5 (1.898, 5.519) (more pro-inflammatory diet)**   ***P***~**trend**~[a](#t2-fn2){ref-type="fn"}
  --------------------------------------------------------------------------- --------------------------------------------------------- --------------------------- --------------------------- -------------------------- ---------------------------------------------------- -----------------------------------------------
  **Breast cancer incidence, *n*=7495, *n* (%)[b](#t2-fn3){ref-type="fn"}**                         1601 (6.52%)                               1538 (6.36%)                1429 (5.82%)                1522 (6.20%)                            1405 (5.72%)                                             
  HR (95% CI), age- and energy-adjusted model                                                           1.00                                 0.98 (0.91, 1.05)           0.91 (0.85, 0.98)          0.97 (0.90, 1.04)                       0.93 (0.86, 1.00)                                        0.09
  HR (95% CI), multivariable-adjusted model[c](#t2-fn4){ref-type="fn"}                                  1.00                                 0.98 (0.91, 1.05)           0.93 (0.86, 1.00)          1.00 (0.93, 1.07)                       0.99 (0.91, 1.07)                                        0.83
  **Breast cancer death**                                                                     **Q1 (−7.055, \<−3.162)**                  **Q2 (−3.162, \<−2.032)**   **Q3 (−2.032, \<−0.374)**   **Q4 (−0.374, \<1.874)**                 **Q5 (1.874, 5.519)**                                         
  **Breast cancer death, *n*=667, *n* (%)[b](#t2-fn3){ref-type="fn"}**                               108 (0.53%)                                127 (0.63%)                 138 (0.68%)                152 (0.75%)                             142 (0.70%)                                              
  HR (95% CI), age- and energy-adjusted model                                                           1.00                                 1.21 (0.94, 1.57)           1.35 (1.05, 1.74)          1.51 (1.18, 1.94)                       1.53 (1.18, 2.00)                                       0.0005
  HR (95% CI), multivariable-adjusted model[c](#t2-fn4){ref-type="fn"}                                  1.00                                 1.15 (0.89, 1.49)           1.25 (0.97, 1.62)          1.38 (1.07, 1.79)                       1.33 (1.01, 1.76)                                        0.03

Abbreviations: CI=confidence interval; HR=hazard ratio; Q=quintile.

The *P*-value for trend was obtained by assigning the median value of each DII quintile to all participants in each quintile.

The proportion of breast cancer events (cases or deaths) in the quintile.

Adjusted for age, energy intake, race/ethnicity, income, education, smoking status, mammography within 2 years of baseline, age at menarche, number of live births, oophorectomy status, hormone therapy use, nonsteroidal anti-inflammatory drug (NSAID) use, dietary modification trial arm, hormone therapy trial arm, body mass index, and physical activity. Calcium and vitamin D (CaD) trial arm violated the proportional hazards assumption and all multivariable-adjusted models were stratified by CaD.

###### Risk of breast cancer by subtype and stage at diagnosis, across quintiles of the dietary inflammatory index (DII); Women\'s Health Initiative (*n*=122 788), 1993--2014

                                                                **Referent** **Q1 (−7.055,\<−3.145) (more anti-inflammatory diet)**   **Q2 (−3.145, \<−2.026)**   **Q3 (−2.026, \<−0.377)**   **Q4 (−0.377, \<1.884)**   **Q5 (1.884, \<5.789) (more pro-inflammatory diet)**   ***P***~**trend**~[a](#t3-fn3){ref-type="fn"}
  ------------------------------------------------------------ --------------------------------------------------------------------- --------------------------- --------------------------- -------------------------- ------------------------------------------------------ -----------------------------------------------
  **Molecular subtypes**                                                                                                                                                                                                                                                       
  ER+ *n*=5943 cases, *n* (%)[b](#t3-fn4){ref-type="fn"}                                   1288 (5.30%)                                     1225 (5.05%)                1138 (4.69%)                1210 (4.99%)                             1082 (4.46%)                                              
  HR (95% CI)                                                                                  1.00                                       0.97 (0.90, 1.05)           0.93 (0.85, 1.00)          1.00 (0.92, 1.08)                        0.97 (0.89, 1.06)                                         0.88
  ER− *n*=1025 cases, *n* (%)                                                               198 (0.86%)                                      212 (0.91%)                 190 (0.81%)                214 (0.92%)                              211 (0.90%)                                               
  HR (95%CI)                                                                                   1.00                                       1.09 (0.90, 1.33)           0.98 (0.80, 1.21)          1.11 (0.91, 1.36)                        1.13 (0.91, 1.41)                                         0.27
  PR+ *n*=5001 cases, *n* (%)                                                              1067 (4.44%)                                     1028 (4.27%)                 966 (4.01%)                1041 (4.32%)                             899 (3.74%)                                               
  HR (95%CI)                                                                                   1.00                                       0.99 (0.90, 1.08)           0.95 (0.87, 1.04)          1.03 (0.95, 1.13)                        0.98 (0.89, 1.08)                                         0.84
  PR− *n*=1859 cases, *n* (%)                                                               398 (1.70%)                                      377 (1.61%)                 344 (1.47%)                372 (1.59%)                              368 (1.56%)                                               
  HR (95%CI)                                                                                   1.00                                       0.97 (0.84, 1.12)           0.90 (0.78, 1.05)          0.98 (0.85, 1.14)                        1.03 (0.87, 1.20)                                         0.60
  HER2+ *n*=771 cases, *n* (%)                                                              139 (0.60%)                                      151 (0.65%)                 163 (0.70%)                178 (0.77%)                              140 (0.60%)                                               
  HR (95% CI)                                                                                  1.00                                       1.11 (0.88, 1.40)           1.21 (0.96, 1.52)          1.33 (1.05, 1.67)                        1.11 (0.85, 1.44)                                         0.24
  HER2− *n*=4731 cases, *n* (%)                                                            1039 (4.33%)                                      953 (3.98%)                 895 (3.73%)                956 (3.98%)                              888 (3.69%)                                               
  HR (95% CI)                                                                                  1.00                                       0.94 (0.86, 1.02)           0.90 (0.82, 0.98)          0.96 (0.88, 1.05)                        0.96 (0.87, 1.07)                                         0.91
  ER−, PR−, HER2+ *n*=205 cases, *n* (%)                                                    35 (0.15%)                                       34 (0.15%)                  47 (0.20%)                  45 (0.19%)                               44 (0.19%)                                               
  HR (95% CI)                                                                                  1.00                                       1.02 (0.63, 1.65)           1.41 (0.90, 2.21)          1.36 (0.86, 2.15)                        1.42 (0.86, 2.34)                                         0.11
  Luminal A (ER+ and/or PR+, HER2−); *n*=4202 cases, *n* (%)                                935 (3.91%)                                      840 (3.52%)                 802 (3.35%)                848 (3.55%)                              777 (3.25%)                                               
  HR (95% CI)                                                                                  1.00                                       0.92 (0.83, 1.01)           0.89 (0.81, 0.98)          0.95 (0.86, 1.05)                        0.94 (0.85, 1.05)                                         0.67
  Luminal B (ER+ and/or PR+, HER2+); *n*=554 cases, *n* (%)                                 104 (0.45%)                                      115 (0.50%)                 113 (0.49%)                128 (0.55%)                               94 (0.40%)                                               
  HR (95% CI)                                                                                  1.00                                       1.11 (0.84, 1.45)           1.10 (0.83, 1.44)          1.25 (0.96, 1.63)                        0.96 (0.70, 1.30)                                         0.96
  Triple negative (ER−, PR−, HER2−); *n*=509 cases, *n* (%)                                 99 (0.43%)                                       109 (0.47%)                 90 (0.39%)                 104 (0.45%)                              107 (0.46%)                                               
  HR (95% CI)                                                                                  1.00                                       1.12 (0.85, 1.48)           0.93 (0.69, 1.24)          1.06 (0.80, 1.42)                        1.11 (0.82, 1.51)                                         0.60
  **Histologic subtypes**                                                                                                                                                                                                                                                      
  Invasive ductal carcinoma; *n*=4767 cases, *n* (%)                                       1007 (4.20%)                                      998 (4.16%)                 917 (3.81%)                962 (4.01%)                              883 (3.67%)                                               
  HR (95% CI)                                                                                  1.00                                       1.00 (0.92, 1.09)           0.93 (0.85, 1.02)          0.98 (0.89, 1.07)                        0.94 (0.85, 1.04)                                         0.26
  Invasive lobular carcinoma; *n*=758 cases, *n* (%)                                        172 (0.74%)                                      151 (0.65%)                 139 (0.60%)                153 (0.66%)                              143 (0.61%)                                               
  HR (95% CI)                                                                                  1.00                                       0.91 (0.73, 1.14)           0.87 (0.69, 1.09)          0.98 (0.78, 1.23)                        1.01 (0.79, 1.30)                                         0.65
  **Stage at diagnosis**                                                                                                                                                                                                                                                       
  Localised; *n*=5567 cases                                                                1217 (5.03%)                                     1054 (4.77%)                1036 (4.29%)                1141 (4.72%)                             1019 (4.22%)                                              
                                                                                               1.00                                       0.94 (0.86, 1.02)           0.99 (0.91, 1.08)          0.99 (0.91, 1.08)                        1.00 (0.88, 1.06)                                         0.97
  Regional/distant; *n*=1799 cases                                                          363 (1.56%)                                      361 (1.54%)                 369 (1.57%)                351 (1.50%)                              355 (1.51%)                                               
                                                                                               1.00                                       1.01 (0.87, 1.17)           0.98 (0.85, 1.15)          0.97 (0.83, 1.13)                        0.84 (0.79, 1.00)                                         0.03

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; HR=hazard ratio; PR=progesterone receptor; Q=quintile.

All models were adjusted for age, race/ethnicity, income, education, body mass index, physical activity, smoking status, mammography within 2 years of baseline, age at menarche, number of live births, oophorectomy status, hormone therapy use, nonsteroidal anti-inflammatory drug (NSAID) use, dietary modification trial arm, hormone therapy trial arm, and energy intake. Calcium and vitamin D (CaD) trial arm violated the proportional hazards assumption and all multivariable-adjusted models were stratified by CaD. Case frequencies were obtained after excluding participants with missing data in the covariates.

The *P*-value for trend was obtained by assigning the median value of each DII quintile to all participants in the quintile.

The proportion of breast cancer events (cases or deaths) in each quintile.

###### Hazard ratios of the association between the dietary inflammatory index (DII) and breast cancer incidence and death, with the exclusion of breast cancer cases and deaths that occurred within 3 years from baseline; Women\'s Health Initiative (*n*=122 788), 1993--2014

  **Breast cancer incidence**                                              **Q1 (−7.055, \<−3.145) (more anti-inflammatory diet)**   **Q2 (−3.145, \<−2.026)**   **Q3 (−2.026, \<−0.377)**    **Q4 (−0.377, \<1.884)**    **Q5 (1.884, \<5.789) (more pro-inflammatory diet)**   ***P***~**trend**~[a](#t4-fn2){ref-type="fn"}
  ----------------------------------------------------------------------- --------------------------------------------------------- --------------------------- ---------------------------- --------------------------- ------------------------------------------------------ -----------------------------------------------
  Breast cancer incidence, *n*=5978, *n* (%)[b](#t4-fn3){ref-type="fn"}                         1264 (5.25%)                               1221 (5.07%)                 1118 (4.64%)                1228 (5.09%)                              1147 (4.76%)                                              
  HR (95% CI), age- and energy-adjusted model                                                       1.00                                 0.99 (0.91, 1.07)           0.91 (0.84, 0.98)            0.99 (0.92, 1.08)                        0.98 (0.89, 1.05)                                         0.71
  HR (95% CI), multivariable-adjusted model[b](#t4-fn3){ref-type="fn"}                              1.00                                 0.99 (0.91, 1.07)           0.92 (0.85, 1.00)            1.01 (0.93, 1.10)                        1.02 (0.93, 1.12)                                         0.31
  **Breast cancer death**                                                                 **Q1 (−7.055, \<−3.165)**                  **Q2 (−3.165, \<−2.040)**   **Q3 (−2.040, \<−0.3889)**   **Q4 (−0.3889, \<1.863)**                  **Q5 (1.863, 5.789)**                                          
  Breast cancer death, *n*=656, *n* (%)[b](#t4-fn3){ref-type="fn"}                               105 (0.52%)                                124 (0.61%)                 137 (0.68%)                  152 (0.75%)                               138 (0.68)                                               
  HR (95% CI), age- and energy-adjusted model                                                       1.00                                 1.21 (0.94, 1.58)           1.38 (1.07, 1.78)            1.56 (1.21, 2.00)                        1.54 (1.18, 2.02)                                        0.0004
  HR (95% CI), multivariable-adjusted model[b](#t4-fn3){ref-type="fn"}                              1.00                                 1.16 (0.89, 1.51)           1.28 (0.99, 1.66)            1.43 (1.10, 1.85)                        1.34 (1.01, 1.79)                                         0.02

Abbreviations: CI=confidence interval; HR=hazard ratio; Q=quintile.

The *P*-value for trend was obtained by assigning the median value of each DII quintile to all participants in each quintile.

The proportion of breast cancer events (cases or deaths) in the quintile.

Adjusted for age, energy intake, race/ethnicity, income, education, smoking status, mammography within 2 years of baseline, age at menarche, number of live births, oophorectomy status, hormone therapy use, nonsteroidal anti-inflammatory drug (NSAID) use, dietary modification trial arm, hormone therapy trial arm, body mass index, and physical activity. Calcium and vitamin D (CaD) trial arm violated the proportional hazards assumption and all multivariable-adjusted models were stratified by CaD.
